Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-099-5 | CAS number: 37625-56-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.5 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 225
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 882 mg/m³
- Explanation for the modification of the dose descriptor starting point:
is corrected for breathing rate (*6.7/10), activity (*1/0.38) and relative absorption (*1/2) to give a corrected inhalation NOAEC of 882 mg/m3
For CAPA 3050, the starting point of 1000 mg/kg bw/d from an oral rat study is corrected for activity breathing rate (*6.7/10), activity (*1/0.38) and relative absorption (*1/2) to give a corrected inhalation NOAEC of 882 mg/m3.For CAPA 3050, the starting point of 1000 mg/kg bw/d from an oral rat study is corrected for activity breathing rate (*6.7/10), activity (*1/0.38) and relative absorption (*1/2) to give a corrected inhalation NOAEC of 882 mg/m3.
- AF for dose response relationship:
- 1
- Justification:
- default value
- AF for differences in duration of exposure:
- 6
- Justification:
- Standard factor: extrapolation from sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- not required: already considered in derivation of the corrected starting point
- AF for other interspecies differences:
- 2.5
- Justification:
- Standard factor
- AF for intraspecies differences:
- 5
- Justification:
- Standard factor for workers
- AF for the quality of the whole database:
- 3
- Justification:
- In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
- AF for remaining uncertainties:
- 1
- Justification:
- default value
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 900
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- In the absence of information on the extent of oral and dermal absorption, these are considered to be equivalent. The corrected dermal starting point is therefore 1000 mg/kg bw/d.
- AF for dose response relationship:
- 1
- Justification:
- default value
- AF for differences in duration of exposure:
- 6
- Justification:
- extrapolation from sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- default value (rat study used to derive the starting point)
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 5
- Justification:
- default value (workers)
- AF for the quality of the whole database:
- 3
- Justification:
- In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
- AF for remaining uncertainties:
- 1
- Justification:
- default value
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
The relevant starting point is the NOAEL of 1000 mg/kg bw/d from the rat developmental toxicity study performed with CAPA 3050; this study is considered to be a sub-acute study according to REACH Guidance. In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
Inhalation DNELs
For workers, the starting point of 1000 mg/kg bw/d from the oral rat study is corrected for breathing volume (/0.38), activity (*0.67) and for the relative extent of oral and inhalation absorption (*0.5) to give a corrected (inhalation) starting point of 882 mg/m3.
Systemic inhalation DNELs
Assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure: extrapolation from sub-acute to chronic duration), 4 for allometric scaling, 2.5 (for interspecies differences), 5 (for intraspecies differences), 3 (for database quality) and 1 (for remaining uncertainties) are combined to give an overall assessment factor of 225. Application of the overall assessment factor to the corrected starting point gives a long-term systemic inhalation DNEL of 3.9 mg/m3 for workers. CAPA 3050 is not classified for acute toxicity. In the absence of any acute hazard, an acute systemic inhalation DNEL is not derived.
Local inhalation DNELs
CAPA 3050 is not an irritant or sensitiser. In the absence of any identified hazard, local inhalation DNEL values are not derived.
Dermal DNELs
In the absence of information on the extent of oral and dermal absorption, these are considered to be equivalent. The corrected dermal starting point is therefore 1000 mg/kg bw/d.
Systemic dermal DNELs
Assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure: extrapolation from sub-acute to chronic duration), 2.5 (for interspecies differences), 5 (for intraspecies differences), 3 (for database quality) and 1 (for remaining uncertainties) are combined to give an overall assessment factor of 900. Application of the overall assessment factor to the corrected starting point gives a long-term systemic dermal DNEL of 1.1 mg/kg bw/d for workers. CAPA 3050 is not classified for acute toxicity. In the absence of any acute hazard, an acute systemic dermal DNEL is not derived.
Local dermal DNELs
CAPA 3050 is not a skin irritant or sensitiser. In the absence of any identified hazard, local dermal DNEL values are not derived.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 450
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 435 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- For the general population, the starting point of 1000 mg/kg bw/d from an oral rat study is corrected for breathing volume (/1.15), and for the relative extent of oral and inhalation absorption (*0.5) to give a corrected (inhalation) starting point of 435 mg/m3.
- AF for dose response relationship:
- 1
- Justification:
- default value
- AF for differences in duration of exposure:
- 6
- Justification:
- extrapolation from a sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- not required: already taken into account in derivation of the modified starting point
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 10
- Justification:
- default value: general population
- AF for the quality of the whole database:
- 3
- Justification:
- In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
- AF for remaining uncertainties:
- 1
- Justification:
- default value
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.6 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 1 800
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- In the absence of information on the extent of oral and dermal absorption, these are considered to be equivalent. The corrected dermal starting point is therefore 1000 mg/kg bw/d.
- AF for dose response relationship:
- 1
- Justification:
- default value
- AF for differences in duration of exposure:
- 6
- Justification:
- extrapolation from a sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- default value (rat study used to derive the starting point)
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 10
- Justification:
- default value: general population
- AF for the quality of the whole database:
- 3
- Justification:
- In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
- AF for remaining uncertainties:
- 1
- Justification:
- default value
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.6 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 1 800
- Dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 000 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Correction of the starting point is not required.
- AF for dose response relationship:
- 1
- Justification:
- default value
- AF for differences in duration of exposure:
- 6
- Justification:
- extrapolation from a sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- default value (rat study used to derive the starting point)
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 10
- Justification:
- default value: general population
- AF for the quality of the whole database:
- 3
- Justification:
- In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
- AF for remaining uncertainties:
- 1
- Justification:
- default value
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
- Modified dose descriptor starting point:
- NOAEL
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The relevant starting point is the NOAEL of 1000 mg/kg bw/d from the rat developmental toxicity study performed with CAPA 3050; this study is considered to be a sub-acute study according to REACH Guidance. In the absence of repeated dose toxicity studies assessing haematological, clinical chemistry or histopathology, an additional assessment factor of 3 for database quality is used for DNEL derivation. This additional factor is considered to be adequately protective based on the demonstrated low toxicity of related substances, components and metabolites of CAPA 3050.
Inhalation DNELs
For the general population, the starting point of 1000 mg/kg bw/d from an oral rat study is corrected for breathing volume (/1.15), and for the relative extent of oral and inhalation absorption (*0.5) to give a corrected (inhalation) starting point of 435 mg/m3.
Systemic inhalation DNELs
Assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure: extrapolation from sub-acute to chronic duration), 4 for allometric scaling, 2.5 (for interspecies differences), 10 (for intraspecies differences), 3 (for database quality) and 1 (for remaining uncertainties) are combined to give an overall assessment factor of 450. Application of the overall assessment factor to the corrected starting point gives a long-term systemic inhalation DNEL of 1.0 mg/m3 for the general population. CAPA 3050 is not classified for acute toxicity. In the absence of any acute hazard, an acute systemic inhalation DNEL is not derived.
Local inhalation DNELs
CAPA 3050 is not an irritant or sensitiser. In the absence of any identified hazard, local inhalation DNEL values are not derived.
Dermal DNELs
In the absence of information on the extent of oral and dermal absorption, these are considered to be equivalent. The corrected dermal starting point is therefore 100 mg/kg bw/d.
Systemic dermal DNELs
Assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure: extrapolation from sub-acute to chronic duration), 2.5 (for interspecies differences), 10 (for intraspecies differences), 3 (for database quality) and 1 (for remaining uncertainties) are combined to give an overall assessment factor of 1800. Application of the overall assessment factor to the corrected starting point gives a long-term systemic dermal DNEL of 0.6 mg/kg bw/d for the general population. CAPA 3050 is not classified for acute toxicity. In the absence of any acute hazard, an acute systemic dermal DNEL is not derived.
Local dermal DNELs
CAPA 3050 is not a skin irritant or sensitiser. In the absence of any identified hazard, local dermal DNEL values are not derived.
Oral DNELs
Correction of the starting point is not required.
Systemic oral DNELs
Assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure: extrapolation from sub-acute to chronic duration), 2.5 (for interspecies differences), 10 (for intraspecies differences), 3 (for database quality) and 1 (for remaining uncertainties) are combined to give an overall assessment factor of 1800. Application of the overall assessment factor to the corrected starting point gives a long-term systemic oral DNEL of 0.6 mg/kg bw/d for the general population. CAPA 3050 is not classified for acute toxicity. In the absence of any acute hazard, an acute systemic oral DNEL is not derived.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
